Fatemeh Montazer

Fatemeh Montazer

Auto-generated profile, based on publicly available information

Fatemeh Montazer

Firoozabadi clinical research development unit (FCRDU), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2017 in BMC Dermatology
Verified
Journal Article
Open access
PDF file
GRGhasem Rahmatpour Rokni
Ghasem Rahmatpour Rokni
FMFatemeh Montazer
Fatemeh Montazer
MSMahnaz Sharifian
Mahnaz Sharifian
Mohamad GoldustMohamad Goldust
Mohamad Goldust
Hemangioendothelioma includes several types of vascular neoplasms , as well as both benign and malignant growth. This study evaluated a case of a 78-year-old female diagnosed with composite hemangioendothelioma (CHE). This patient had an 18-month history of painless inflammatory lesions and erythema on the left forehead and right upper eyelid. The clinical and pathologic characteristics of the CHE were evaluated in the present study. The evidence of the coexistence of variable components of the CHE in our study emphasized the importance of distinctive morphology and biology, and should be considered in the differential diagnosis of other vascular lesions.

1 January 2019
Verified
Journal Article
Open access
PDF file
RSRamin Shekarriz
Ramin Shekarriz
FMFatemeh Montazer
Fatemeh Montazer
RAReza Alizadeh-Navaei
Reza Alizadeh-Navaei
Background: To determine the expression of cancer stem cell marker Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) in colorectal carcinoma samples compared to normal adjacent tissue and any possible association with clinicopathological findings. Methods: This study was performed on forty samples of cancerous colorectal tissues (case group) and their adjacent normal ...

1 January 2019 in Indian Journal of Dermatology, Venereology and Leprology
Verified
Journal Article
Open access
NGNarges Ghandi
Narges Ghandi
SFShabnam Fahim
Shabnam Fahim
FMFatemeh Montazer
Fatemeh Montazer
HTHamidReza Tohidinik
HamidReza Tohidinik
ZNZahraSafaei Naraghi
ZahraSafaei Naraghi
MNMaryam Nasimi
Maryam Nasimi
Indian J Dermatol Venereol Leprol, Official publication of Indian Prosthodontic Society

17 August 2023 in Cancer Reports
Verified
Journal Article
Open access
PFPedram Fadavi
Pedram Fadavi
MGMaryam Garousi
Maryam Garousi
SSSepideh Soltani
Sepideh Soltani
FMFatemeh Montazer
Fatemeh Montazer
MAMaryam Abolhasani
Maryam Abolhasani
EMElahe Mirzaee
Elahe Mirzaee
Background: In patients with uterine adenosarcoma, a total abdominal hysterectomy (TAH) with bilateral salpingo‐oophorectomy (BSO) is typically recommended as an initial treatment. There is no consensus on adjuvant therapies.Case: We report the case of a patient with uterine adenosarcoma with postoperative residual disease. We performed four courses of adjuvant chemotherapy, including Ifosfamide, Mesna, and Adriamycin, and whole pelvic radiation with a dose of 50.4 Gy/28 Fr.Conclusion: A combination of chemotherapy and radiotherapy may be a promising treatment option for uterine adenosarcoma with postoperative residual disease.

9 August 2023 in Cancer Reports
Verified
Journal Article
Open access
RSRazieh Shahnazari
Razieh Shahnazari
FMFatemeh Montazer
Fatemeh Montazer
SSShahriar Shirzadi
Shahriar Shirzadi
SKSina Karaji
Sina Karaji
Background: Chondrosarcomas are an exceedingly rare form of cancer, impacting only a few individuals per million. Among chondrosarcomas, a small fraction belongs to the mesenchymal sub‐type. Furthermore, only one‐third of mesenchymal chondrosarcomas manifest in extraskeletal locations.Case: A 38‐year‐old woman was referred by a midwife after experiencing pain in the right upper quadrant of her right breast for 2 months. The mass had been palpable for 1 week before the initial assessment. According to radiological evaluations, the tumor is outside breast tissue and not connected to the bones. Hence, a biopsy of the mass is done. The biphasic morphology of the tumor during pathological evaluation, in addition to immunohistochemistry testing, confirms the diagnosis of extraskeletal mesenchymal chondrosarcoma (EMCS). Finally, the mass was surgically removed, and 6 months of chemotherapy were administered to the patient.Conclusion: Given the tumor's rarity and the lack of established guidelines, diagnosing EMCS can be challenging and prone to errors. As such, meticulous sampling, along with precise pathological and imaging investigations, is imperative to accurately establish the diagnosis of these tumors.

22 August 2019 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
AAAhmad Alikhani
Ahmad Alikhani
SRSiavash Rahimi
Siavash Rahimi
AKArmaghan Kazeminejad
Armaghan Kazeminejad
FMFatemeh Montazer
Fatemeh Montazer